DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy?

DBV Technologies S.A. (NASDAQ:DBVT) shares gapped up before the market opened on Friday . The stock had previously closed at $18.80, but opened at $20.19. DBV Technologies shares last traded at $20.9450, with a volume of 225,306 shares.

Wall Street Analysts Forecast Growth

DBVT has been the topic of a number of analyst reports. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Citizens Jmp upped their price objective on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research report on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on DBV Technologies in a research report on Thursday, December 18th. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.38.

DBV Technologies Trading Up 10.5%

The company has a market cap of $834.44 million, a price-to-earnings ratio of -4.02 and a beta of -1.17. The stock’s 50 day moving average price is $16.67 and its 200 day moving average price is $13.16.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares of the company’s stock, valued at $41,688,039.20. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.44% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Vivo Capital LLC acquired a new position in DBV Technologies in the second quarter valued at $9,659,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of DBV Technologies in the 2nd quarter worth about $9,659,000. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies in the 2nd quarter valued at about $9,649,000. Octagon Capital Advisors LP purchased a new stake in shares of DBV Technologies during the 2nd quarter worth about $9,315,000. Finally, Millennium Management LLC increased its position in DBV Technologies by 26.1% during the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after purchasing an additional 69,849 shares in the last quarter. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.